NUVB · Nuvation Bio Inc.

Track NUVB — free

$5.00 +0.05 (+1.01%) At close · Oct 9

Russell 2000 member Rebalance outlook locked

Market Cap

$1.76B

351.12M

Volume · Oct 9 2.96M Avg daily vol (3M) 5.61M

Up next

Next earnings call

Nov 5, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$169.90M

Trailing 12 months

Net income (TTM)

−$149.83M

Trailing 12 months

Revenue growth YoY

+555.6%

Year over year

Operating margin

-81.0%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$412.44M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.4%

Year over year · more shares

Price change (1Y)

+33.3%

Trailing year

Short interest

16.8%

Latest settlement · 13.9 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 14.8 · calm Equity put/call 0.56

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −12%

below

Price vs 50-day avg −19%

below

RSI (14) 31

neutral

MACD trend Negative

52-week position 26%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −18%

trailing

6-month return −2%

trailing

YTD return −44%

this year

Relative strength −12%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $6 › 200d $6 — 50d above 200d

Institutional flow Accumulating

8 of 245 funds reported for Sep 30 · net +20.7K sh shares · +2 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

16.76% of float · ▲ +1.2% MoM · 13.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

245 holders — near 3-yr high, broad support

Squeeze score 68

elevated · 0–100

Fundamentals

Excellent

Revenue growth +699%

Y/Y

Gross margin 1%

expanding

EPS growth +72%

Y/Y

Balance sheet $111.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 85%

annualized · 1-yr

Max drawdown −58%

past year

ATR 5.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 1, 2022

Decrease in annual operating costs from workforce reduction · annual $11.8M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−12% Bearish

Price vs 50-day avg

−19% Bearish

RSI (14)

31 Neutral

MACD trend

Negative Bearish

52-week position

26% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $6 › 200d $6 — 50d above 200d

Institutional flow Accumulating

8 of 245 funds reported for Sep 30 · net +20.7K sh shares · +2 new

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

16.76% of float · ▲ +1.2% MoM · 13.9 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

245 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $3 Now $5 · 26% Range high $10

vs 200-day avg -12% vs 50-day avg -19%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
new patient starts	160	second quarter of 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
NUVB Nuvation Bio Inc. this stock	$1.76B	-44.2%	+699.0%	—	16.8%
VRTX Vertex Pharmaceuticals Inc / Ma	$129.29B	+12.5%	+46.2%	29.7	1.8%
MRNA Moderna, Inc.	$89.83B	+663.0%	+4.3%	—	7.7%
REGN Regeneron Pharmaceuticals, Inc.	$76.86B	-3.3%	+20.8%	18.5	2.1%
CSLLY Csl Ltd	$61.83B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

246

% held: 68.4%
Reported: 8 of 245
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

189

View

Short & Settlement

Short Interest Rising

Shares short

58.9M

Days to cover: 13.9d
Change: +689.2K sh

View

Short Volume

Short vol %

58%

As of: Oct 9, 2026

Short Total

View

Fails to Deliver

FTD shares

1.1K

Value: $7.2K
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

38.6%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$62.9M

Net income (FY): $-204.6M
EPS diluted: $-0.60

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 6, 2026
This year: 13

View

Proposed Sales

Value

$696.0K

Shares: 100.0K
Filed: Aug 19, 2026

View

Earnings & Events

Webcasts

Last webcast

Aug 6, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
NUVB	-2.7%	-17.6%	-2.3%	-10.7%	-44.2%
SPY	+1.2%	+1.9%	+9.9%	+2.1%	+14.2%
vs SPY	-3.9%	-19.5%	-12.2%	-12.8%	-58.4%

Key facts CIK 1811063 CUSIP 67080N101 13F (30d) 8 filings 8 filers Visit website Investor relations

NUVB · Nuvation Bio Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance